Saturday, June 20, 2020 10:53:36 AM
What other Pharma climbed to a 70 billion market cap within , lets guess 3 to 5 years? Who cares, They don't have Leron. Does Gilead have anything close to Leron? Do readers listen to the TV ads about side effects of the drugs approved by the FDA. If you take this your hair falls out shortly after you loose a leg and arm. I laugh about the side effects.
What side effects does Leron have? Nothing. Thinking, thinking. None.
Our market; HIV, All the flue types.
22 types of Cancer. Did I write Cancer? Billions. We, CYDY could be doing 70 Billion in Revenue from all the Cancer, Flu, and HIV in 5 years. 70 billion X 10 = what market cap? 700 Billion or 700$ a share. Yes, I am conservative.
Readers are now thinking. Just maybe.
I have witnessed this kind of return with close to 10 of my largest positions as a broker and a venture cap investor. Think BIG PICTURE.
This is my Big Picture. All investors will have unique Paintings. If an investor wants a buy out? Fine. I hope by that time our cash flow allows a CYDY tender offer at a premium to market price. That removes those with that Pig Picture and up the stock price climbs.
What side effects does Leron have? Nothing. Thinking, thinking. None.
Our market; HIV, All the flue types.
22 types of Cancer. Did I write Cancer? Billions. We, CYDY could be doing 70 Billion in Revenue from all the Cancer, Flu, and HIV in 5 years. 70 billion X 10 = what market cap? 700 Billion or 700$ a share. Yes, I am conservative.
Readers are now thinking. Just maybe.
I have witnessed this kind of return with close to 10 of my largest positions as a broker and a venture cap investor. Think BIG PICTURE.
This is my Big Picture. All investors will have unique Paintings. If an investor wants a buy out? Fine. I hope by that time our cash flow allows a CYDY tender offer at a premium to market price. That removes those with that Pig Picture and up the stock price climbs.
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
